

## TRAVITCH STUDY

Efficacy and tolerance of a novel topical TRPV-1 channel antagonist in dogs with pruritic pododermatitis: an open pilot study



72%

Reduction pruritus  
VAS score

Veterinarians considered the  
efficacy good or excellent in

100% of the cases

### STUDY AUTHORS

Xavier Serra Fabregat **Clínica Veterinaria Más que Gossos** Elena Diéguez **Anicura Abros** Miguel Ángel de Pablo **Evidencia Hospital Mediterráneo** Conchita Hernán-Pérez **Centauro Veterinarios** Oliver Valero-Coppin **Universitat Autònoma de Barcelona**  
Elsa Genove Corominas **Vetilea**

# Travaderm is effective and well tolerated for pododermatitis in dogs

## MATERIALS AND METHODS

The study was open, **multicentric with 24 client-owned dogs** with **pododermatitis**. All dogs complied inclusion and exclusion criteria and were treated only with **Travaderm spray** twice daily for 28 days.

The following parameters were evaluated:


- Pruritus through the Pruritus Visual Analog Scale (PVAS)
- Lesion severity through a CADESI-3 score adapted for pododermatitis
- Quality of Life score (QoL)
- Presence or absence of secondary infections
- Subjective efficacy perception by the veterinarian and pet owner

## HYPOTHESIS

The reduction of mean values on all the variables is equal or superior **to 50%**

## RESULTS

The results show that the hypothesis was achieved, **reducing significantly the initial indexes more than 50%**



**1\_ Mean reduction of itch**  
(Table 1, Figure 2).



**2\_ Patients end the study with an itch value considered as normal**



**3\_ Reduction in the adapted CADESI-3 score**  
(Figure 2, Photo 1-4).



**4\_ Veterinarians considered the efficacy good or excellent**



**5\_ Pet owners considered the efficacy good or excellent**



**6\_ Recovery of secondary infections**

## 7\_Improves the Quality of Life index (Table 1, Figura 3)

8\_Tolerance was good, there was only one adverse event (increased erythema) which was transient and lasted a few days.

VARIABLE	VALOR MEDIO INICIAL	VALOR MEDIO FINAL	P-VALUE
pVAS (cm)	6.7	1.9	< 0.001
Adapted CADESI-3 index	52.2	13.4	< 0.001
QoL Index	8.6	2.2	< 0.001
Secondary infections	18	2	< 0.001

Table 1: Summary of initial and final values of the measured variables and statistical significance




Figure 1: Mean PVAS (±SD) on days 0, 3, 14, 21 and 28




Figure 2: Mean adapted CADESI-3 (±SD) on days 0, 3, 14, 21 and 28.




Figure 3: Vaean QoL (±SD) on days 0, and 28.




PHOTO 1




PHOTO 2



PHOTO 3



PHOTO 4

# VETILEA TRAVADERM



**For localized pruritus.**  
Helps reducing the neural stimulation of pruritus and to interrupt the itch-scratch cycle

## INSTRUCTIONS OF USE

Apply about 10 cm from the skin twice a day on the affected area and leave on for at least 10 min.

As maintenance, apply twice a week on the normally affected area.

## COMPOSITION

Isopropyl Myristate, Coco-Caprylate/-Caprate, Prunus Amygdalus Dulcis Oil, Ethoxydiglycol, Hydroxymethoxyiodobenzyl Glycolamide Pelargonate, Tocopheryl Acetate. Sin parabenos.

## FORMAT

Each box contains a 60 ml bottle



**BREAKS THE ITCH-  
SCRATCH CYCLE**



**PATENTED  
PRODUCT**



**NEW MECHANISM OF  
ACTION: TRPV1  
ANTAGONIST**



## MORE INFORMATION

Scan this code to obtain more information about this product

# VETILEA

Vetilea SL  
c/ Sant Gabriel 50  
08950 Esplugues de Llobregat | Barcelona  
[myvetilea.com](http://myvetilea.com) | [info@vetilea.com](mailto:info@vetilea.com)



POWERED BY  
**Galenicum**  
believe in life